Patents by Inventor Thomas Helleday

Thomas Helleday has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted benzodiazoles and use thereof in therapy
    Patent number: 11970474
    Abstract: There is provided herein a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, X1, X2, Y1 to Y4, Z1 to Z3 and n have meanings provided in the description.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: April 30, 2024
    Assignee: THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING
    Inventors: Armando Cázares-Körner, Thomas Helleday, Torkild Visnes, Olov Wallner, Tobias Koolmeister
  • 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY
    Publication number: 20230110478
    Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof. The compound is useful in therapy, e.g. for the treatment of cancers, inflammation, autoimmune diseases and graft-versus host diseases (e.g. in transplantation patients). A pharmaceutical composition comprising the compound or its salt and a method for preparing the compound.
    Type: Application
    Filed: October 14, 2022
    Publication date: April 13, 2023
    Inventors: Christoffer BENGTSSON, Sanjay BORHADE, Martin HARALDSSON, Thomas HELLEDAY, Martin HENRIKSSON, Evert HOMAN, Cynthia PAULIN, Lars SANDBERG, Martin SCOBIE, Pål STENMARK, Karl VALLIN
  • 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy
    Patent number: 11504368
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound is useful in therapy, e.g. for the treatment of cancers, inflammation, autoimmune diseases and graft-versus host diseases (e.g. in transplantation patients). A pharmaceutical composition comprising the compound or its salt and a method for preparing the compound.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: November 22, 2022
    Assignee: THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING
    Inventors: Christoffer Bengtsson, Sanjay Borhade, Martin Haraldsson, Thomas Helleday, Martin Henriksson, Evert Homan, Cynthia Paulin, Lars Sandberg, Martin Scobie, Pål Stenmark, Karl Vallin
  • METHOD FOR TREATING CANCER USING A COMBINATION OF CHK1 AND ATR INHIBITORS
    Publication number: 20220249489
    Abstract: The present invention relates to methods of treating cancer in a patient by administering a compound useful as an inhibitor of ATR protein kinase in combination with a compound useful as an inhibitor of Chk1 protein kinase. The aforementioned combination displays a surprising synergistic effect in treating cancer despite the targeted protein kinases being within the same biological pathway. Moreover, the present invention also relates to methods of treating cancer by administering a compound useful as an inhibitor of ATR protein kinase; administering a compound useful as an inhibitor of Chk1 protein kinase; as well as administering a DNA damaging agent to a patient. The compounds utilized in this invention are represented by formula I and formula II: wherein the variables are as defined herein.
    Type: Application
    Filed: September 20, 2021
    Publication date: August 11, 2022
    Inventors: Thomas HELLEDAY, Kumar SANJIV
  • USE OF RNAI INHIBITING PARP ACTIVITY FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CANCER
    Publication number: 20220062286
    Abstract: The present invention relates to the use of an agent that inhibits the activity of an enzyme that mediates repair of a DNA strand break in the manufacture of a medicament for the treatment of diseases caused by a defect in a gene that mediates homologous recombination.
    Type: Application
    Filed: November 16, 2021
    Publication date: March 3, 2022
    Inventor: Thomas Helleday
  • Method for treating cancer using a combination of Chk1 and ATR inhibitors
    Patent number: 11179394
    Abstract: The present invention relates to methods of treating cancer in a patient by administering a compound useful as an inhibitor of ATR protein kinase in combination with a compound useful as an inhibitor of Chk1 protein kinase. The aforementioned combination displays a surprising synergistic effect in treating cancer despite the targeted protein kinases being within the same biological pathway. Moreover, the present invention also relates to methods of treating cancer by administering a compound useful as an inhibitor of ATR protein kinase; administering a compound useful as an inhibitor of Chk1 protein kinase; as well as administering a DNA damaging agent to a patient. The compounds utilized in this invention are represented by formula I and formula II: wherein the variables are as defined herein.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: November 23, 2021
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Thomas Helleday, Kumar Sanjiv
  • NOVEL FUNCTIONALIZED PURINE-2,6-DIONES AND THEIR USE IN MEDICINE
    Publication number: 20210128566
    Abstract: There is provided compounds of formula (I), or pharmaceutically-acceptable salts thereof, wherein R1 to R4 and X1 to X5 have meanings provided in the description, which compounds are useful in the treatment of cancers.
    Type: Application
    Filed: July 27, 2018
    Publication date: May 6, 2021
    Inventors: Brent PAGE, Nicholas VALERIE, Thomas HELLEDAY, Olov WALLNER, Martin SCOBIE, Sabin LLONA-MINGUEZ
  • 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY
    Publication number: 20210052587
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound is useful in therapy, e.g. for the treatment of cancers, inflammation, autoimmune diseases and graft-versus host diseases (e.g. in transplantation patients). A pharmaceutical composition comprising the compound or its salt and a method for preparing the compound.
    Type: Application
    Filed: April 17, 2019
    Publication date: February 25, 2021
    Inventors: Christoffer BENGTSSON, Sanjay BORHADE, Martin HARALDSSON, Thomas HELLEDAY, Martin HENRIKSSON, Evert HOMAN, Cynthia PAULIN, Lars SANDBERG, Martin SCOBIE, Pål STENMARK, Karl VALLIN
  • SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY
    Publication number: 20210002250
    Abstract: There is provided herein a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, X1, X2, Y1 to Y4, Z1 to Z3 and n have meanings provided in the description.
    Type: Application
    Filed: March 1, 2019
    Publication date: January 7, 2021
    Inventors: Armando CÁZARES-KÖRNER, Thomas HELLEDAY, Torkild VISNES, Olov WALLNER, Tobias KOOLMEISTER
  • USE OF RNAI INHIBITING PARP ACTIVITY FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CANCER
    Publication number: 20200237762
    Abstract: The present invention relates to the use of an agent that inhibits the activity of an enzyme that mediates repair of a DNA strand break in the manufacture of a medicament for the treatment of diseases caused by a defect in a gene that mediates homologous recombination.
    Type: Application
    Filed: October 10, 2019
    Publication date: July 30, 2020
    Inventor: Thomas Helleday
  • MTH1 inhibitors for treatment of inflammatory and autoimmune conditions
    Patent number: 10632125
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of autoimmune diseases and inflammatory conditions.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: April 28, 2020
    Assignee: THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING
    Inventors: Martin Scobie, Olov Wallner, Tobias Koolmeister, Karl Sven Axel Vallin, Carl Martin Henriksson, Evert Homan, Thomas Helleday, Sylvain Jacques, Roland Julius Yu Fiskesund
  • MTH1 inhibitors for treatment of cancer
    Patent number: 10179790
    Abstract: A compound of formula I, (I) or a pharmaceutically-acceptable salt thereof. The compound is useful in the treatment of cancer.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: January 15, 2019
    Assignee: THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING
    Inventors: Martin Scobie, Olov Wallner, Tobias Koolmeister, Karl Sven Axel Vallin, Carl Martin Henriksson, Sylvain Jacques, Evert Homan, Thomas Helleday
  • Pyrimidine-2,4-diamine derivatives for treatment of cancer
    Patent number: 10174029
    Abstract: A compound of formula I, or a pharmaceutically-acceptable salt thereof. The compound is useful in the treatment of cancer or other diseases that may benefit from inhibition of MTH1.
    Type: Grant
    Filed: February 19, 2018
    Date of Patent: January 8, 2019
    Assignee: THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING
    Inventors: Martin Scobie, Thomas Helleday, Tobias Koolmeister, Sylvain Jacques
  • MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS
    Publication number: 20190000856
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of autoimmune diseases and inflammatory conditions.
    Type: Application
    Filed: August 31, 2018
    Publication date: January 3, 2019
    Inventors: Martin Scobie, Olov Wallner, Tobias Koolmeister, Karl Sven Axel Vallin, Carl Martin Henriksson, Evert Homan, Thomas Helleday, Sylvain Jacques, Roland Julius Yu Fiskesund
  • MTH1 inhibitors for treatment of inflammatory and autoimmune conditions
    Patent number: 10064869
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of autoimmune diseases and inflammatory conditions.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: September 4, 2018
    Assignee: THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING
    Inventors: Martin Scobie, Olov Wallner, Tobias Koolmeister, Karl Sven Axel Vallin, Carl Martin Henriksson, Evert Homan, Thomas Helleday, Sylvain Jacques, Matthieu Desroses, Marie-Caroline Jacques-Cordonnier, Roland Julius Yu Fiskesund
  • PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER
    Publication number: 20180170929
    Abstract: A compound of formula I, or a pharmaceutically-acceptable salt thereof. The compound is useful in the treatment of cancer or other diseases that may benefit from inhibition of MTH1.
    Type: Application
    Filed: February 19, 2018
    Publication date: June 21, 2018
    Inventors: Martin SCOBIE, THOMAS HELLEDAY, TOBIAS KOOLMEISTER, SYLVAIN JACQUES, MATTHIEU DESROSES, MARIE-CAROLINE JACQUES-CORDONNIER
  • Bisarylsulfonamides useful in the treatment of inflammation and cancer
    Patent number: 10000449
    Abstract: A compound of formula (I) useful for the treatment of cancer, inflammation and inflammatory disorders, and a pharmaceutical composition containing the compound.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: June 19, 2018
    Assignee: Kancera AB
    Inventors: Jessica Martinsson, Katarina Faernegardh, Mattias Joensson, Rune Ringom, Nina Gustafsson Sheppard, Thomas Helleday, Petra Groth
  • Pyrimidine-2,4-diamine derivatives for treatment of cancer
    Patent number: 9944640
    Abstract: A compound of formula I, or a pharmaceutically-acceptable salt thereof. The compound is useful in the treatment of cancer or other diseases that may benefit from inhibition of MTH1.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: April 17, 2018
    Assignee: THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING
    Inventors: Martin Scobie, Thomas Helleday, Tobias Koolmeister, Sylvain Jacques, Matthieu Desroses, Marie-Caroline Jacques-Cordonnier
  • Use of RNAI Inhibiting PARP Activity for the Manufacture of a Medicament for the Treatment of Cancer
    Publication number: 20180000822
    Abstract: The present invention relates to the use of an agent that inhibits the activity of an enzyme that mediates repair of a DNA strand break in the manufacture of a medicament for the treatment of diseases caused by a defect in a gene that mediates homologous recombination.
    Type: Application
    Filed: July 14, 2017
    Publication date: January 4, 2018
    Inventor: Thomas Helleday
  • HETEROCYCLIC COMPOUNDS AS DCTPP1 MODULATORS
    Publication number: 20170305893
    Abstract: The invention relates to compounds of formula I, or a pharmaceutically-acceptable salt thereof. The present invention also relates to pharmaceutical formulations comprising these compounds, and to their use as medicaments for the treatment of disorders where modulation of DCTPP (deoxycytidine triphosphate pyrophosphatase 1) activity exerts a therapeutic effect.
    Type: Application
    Filed: October 8, 2015
    Publication date: October 26, 2017
    Inventors: Sabin LLONA-MINGUEZ, Andreas HOGLUND, Sylvain JACQUES, Lars JOHANSSON, Tobias KOOLMEISTER, Martin SCOBIE, Thomas HELLEDAY